AdvaMed Statement on the Klomp Nomination
- Coverage & Payment
- Diagnostics
- Digital Health
- Government & Legislative Affairs
- Health Access
- Regulatory Affairs
WASHINGTON—Scott Whitaker, president and CEO of AdvaMed, the largest trade association representing medtech innovators, posted his statement on LinkedIn regarding the nomination of Chris Klomp as deputy secretary of the Department of Health and Human Services:
https://www.linkedin.com/feed/update/urn:li:share:7476339373047951360/
Related Reading
Blog / Diagnostics / Government & Legislative Affairs / Health Access / Regulatory Affairs
Fixing Medicare’s Lab Payment System: Why the RESULTS Act Matters
November 18, 2026
Clinical laboratory tests are critical to how clinicians screen for disease, diagnose conditions, guide treatment, and monitor outcomes for patients with diabetes, cancer, heart disease, and more.
Blog / Government & Legislative Affairs / Health Access / Regulatory Affairs
Protecting Patient Access to Ostomy and Urological Supplies
November 18, 2026
For roughly one million Americans, ostomy and urological supplies are essential. Whether it is from a condition at birth, result of injury or trauma, or cancer- these products replace or support lost bowel and bladder function. Because they are so personal, each product must match a patient’s anatomy, skin, and daily needs. A poor fit or faulty product can easily lead to leakage, skin breakdown harming a person, and reduced quality of life. If these issues aren’t addressed-the problems compound leading to infection, and hospitalization.
Resource / Government & Legislative Affairs / Health Access / Regulatory Affairs
U.S. Evidence Snapshot: Medtech Saves Lives
November 17, 2026
U.S. life expectancy has reached its highest level in history. Age-adjusted death rates for the leading causes of death dropped from 2023 to 2024, according to preliminary CDC data.
Resource / Artificial Intelligence (AI) / Regulatory Affairs
Comments on FDA’s PMA eSTAR Draft Guidance
November 17, 2026
In this AdvaMed® Comment Letter to FDA, AdvaMed responds to the agency’s draft guidance on the electronic submission template (eSTAR) for premarket approval (PMA) applications. With eSTAR set to become mandatory for PMAs, AdvaMed calls for a template that keeps today’s flexibility, handles large files, and is built and updated through a clear, open, and predictable process. These changes would help medtech companies prepare complete submissions and help FDA review them more efficiently.
News / Global & Trade / Health Access
AdvaMed Congratulates Phil Agress on Foreign Minister’s Commendation from Japan
November 16, 2026
WASHINGTON, D.C.—AdvaMed today congratulated Phil Agress, former senior vice president of Global Strategy and Analysis, on receiving the Foreign Minister’s Commendation from the Government of Japan for his outstanding contributions to promoting economic relations between Japan and the United States. Japan’s Ambassador to the United States, the Honorable Shigeo Yamada, hosted the award presentation.
Blog / Health Access
To Make Americans Healthier, We Need to Prioritize Sleep
November 9, 2026
Sleep is the foundation of health. We spend a lot of time talking about nutrition and exercise. But one important topic still gets too little attention in conversations about our overall health: How are you sleeping? Do you wake up feeling well rested? The answers to those questions can open the door to understanding how you sleep, and subsequently, potential impact on your overall health.
Resource / Digital Health / Global & Trade / Regulatory Affairs
EY Pulse of the MedTech Industry Report 2026
November 5, 2026
The 20th edition of the EY Pulse of the MedTech Industry Report captures the medical devices sector at both a high point and a turning point.
Resource / Government & Legislative Affairs / Regulatory Affairs
Justin Klein Op-Ed: CMS Can Make RAPID a Win for Patients and American Medtech Innovation
November 5, 2026
In this op-ed published in Medtech Insight, Justin Klein, MD, JD, explains how the proposed RAPID coverage pathway could accelerate Medicare access to breakthrough medical technologies and why targeted refinements are essential to its success.
Call to Action Heading…
Call to Action Description…